Arkolith/Insider Trading/CTMX/Form 4/A

Belvin Marcia

SVP, Chief Scientific OfficerCytomX Therapeutics, Inc. (CTMX) · full profile →Form 4/A · filed Feb 10, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 4, 2025Grant(A)58K—$0268K
Feb 4, 2025Grant(A)35K—$0211K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 4, 2025Grant(A)150K—$0150K
Feb 4, 2025Grant(A)115K—$0115K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0001610717-25-000020) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML